Interní Med. 2016; 18(4): 163-167 | DOI: 10.36290/int.2016.038

EMPA-REG OUTCOME and reduction of the risk of heart failure in patients with diabetes

doc.MUDr.David Karásek, Ph.D.
III. interní klinika &ndash, nefrologická, revmatologická a endokrinologická FN a LF UP Olomouc

Type 2 diabetes is a serious disease with rising prevalence. Chronic heart failure substantially contributes to high cardiovascular

mortality in diabetics. All available pharmacological and non-pharmacological therapeutic methods used in the general population

with regard to the special pathogenetic mechanism of heart failure in diabetics and with regard to the results of a series

of intervention studies can be applied. Recently, the selection of hypoglycemic treatments that may influence the prognosis of

diabetic patients with heart failure is emphasized. EMPA-REG OUTCOME is the first prospective, randomized study that demonstrated

a positive effect of antidiabetic therapy to reduce the risk of heart failure.

Keywords: diabetes mellitus, heart failure, antidiabetics, gliflozins, empagliflozin, EMPA-REG OUTCOME

Published: September 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Karásek D. EMPA-REG OUTCOME and reduction of the risk of heart failure in patients with diabetes. Interní Med. 2016;18(4):163-167. doi: 10.36290/int.2016.038.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. http://www.uzis.cz/rychle-informace/cinnost-oboru-diabetologie-pece-diabetiky-roce-2013.
    2. Škrha J, et al. Diabetologie. Praha: Galén 2009, první vydání, 417 s.
    3. Špinar J, Vítovec J, Hradec J, et al. Doporučený postup České kardiologické společnosti pro diagnostiku a léčbu chronického srdečního selhání, 2011. Cor Vasa 2012; 54: e113-e134. Go to original source...
    4. Thrainsdottir IS, Aspelund T, Thorgeirsson G, et al. The association between glucose abnormalities and heart failure in the population-based Reykjavik study. Diabetes Care 2005; 28: 612-616. Go to original source...
    5. Iribarren C, Karter AJ, Go AS, et al. Glycemic control and heart failure among adult patients with diabetes. Circulation 2001; 103: 2668-2673. Go to original source...
    6. Dei Cas A, Fonarow GC, Gheorghiade M, Butler J. Concomitant diabetes mellitus and heart failure. Curr Probl Cardiol 2015; 40: 7-43. Go to original source...
    7. Cubbon RM, Adams B, Rajwani A, et al. Diabetes mellitus is associated with adverse prognosis in chronic heart failure of ischaemic and non-ischaemic aetiology. Diab Vasc Dis Res 2013; 10: 330-336. Go to original source... Go to PubMed...
    8. Sarma S, Mentz RJ, Kwasny MJ, et al. EVEREST investigators. Association between diabetes mellitus and post-discharge outcomes in patients hospitalized with heart failure: findings from the EVEREST trial. Eur J Heart Fail 2013; 15: 194-202. Go to original source... Go to PubMed...
    9. Greenberg BH, Abraham WT, Albert NM, et al. Influence of diabetes on characteristics and outcomes in patients hospitalized with heart failure: a report from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Am Heart J 2007; 154: 277.e1-8. Go to original source... Go to PubMed...
    10. Nieminen MS, Brutsaert D, Dickstein K, et al. EuroHeart Survey Investigators; Heart Failure Association, European Society of Cardiology. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J 2006; 27: 2725-2736. Go to original source... Go to PubMed...
    11. Pelikánová T, Bartoš V, a kol. Praktická diabetologie. Praha: Maxdorf 2011; 5. vydání, 742 s.
    12. Bugger H, Abel ED. Rodent models of diabetic cardiomyopathy. Dis Model Mech 2009; 2: 454-466. Go to original source...
    13. Herrero P, Peterson LR, McGill JB, el al. Increased myocardial fatty acid metabolism in patients with type 1 diabetes mellitus. J Am Coll Cardiol 2006; 47: 598-604. Go to original source...
    14. Sharma S, Adrogue JV, Golfman L, et al. Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. FASEB J 2004; 18: 1692-1700. Go to original source... Go to PubMed...
    15. Hartog JW, Voors AA, Bakker SJ, et al. Advanced glycation end-products (AGEs) and heart failure: pathophysiology and clinical implications. Eur J Heart Fail 2007; 9: 1146-1155. Go to original source... Go to PubMed...
    16. Way KJ, Isshiki K, Suzuma K, et al. Expression of connective tissue growth factor is increased in injured myocardium associated with protein kinase C beta2 activation and diabetes. Diabetes 2002; 51: 2709-2718. Go to original source... Go to PubMed...
    17. Adameova A, Dhalla NS. Role of microangiopathy in diabetic cardiomyopathy. Heart Fail Rev 2014; 19: 25-33. Go to original source... Go to PubMed...
    18. Semplicini A, Ceolotto G, Massimino M, et al. Interactions between insulin and sodium homeostasis in essential hypertension. Am J Med Sci 1994; 307(Suppl 1): S43-46. Go to PubMed...
    19. Westerbacka J, Yki-Järvinen H. Arterial stiffness and insulin resistance. Semin Vasc Med 2002; 2: 157-164. Go to original source... Go to PubMed...
    20. Hradec J. Léčba srdečního selhání u diabetiků. Vnitř Lék 2014; 60: 310-315. Go to PubMed...
    21. Authors/Task Force Members, Rydén L, Grant PJ, Anker SD, et al.; ESC Committee for Practice Guidelines (CPG), Zamorano JL, Achenbach S, Baumgartner H, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 2013; 34: 3035-3087. Go to original source... Go to PubMed...
    22. Giamouzis G, Triposkiadis F, Butler J. Metformin use in patients with diabetes mellitus and heart failure: friend or foe? J Card Fail 2010; 16: 207-210. Go to original source... Go to PubMed...
    23. Eurich DT, Weir DL, Majumdar SR, et al. Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34,000 patients. Circ Heart Fail 2013; 6: 395-402. Go to original source... Go to PubMed...
    24. Haluzík M, Trachta P, Mráz M. Léčba inzulinem a kardiovaskulární komplikace. DMEV 2013; 16: 138-143.
    25. Gilbert RE, Krum H. Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy. Lancet 2015; 385: 2107-2117. Go to original source... Go to PubMed...
    26. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-2471. Go to original source... Go to PubMed...
    27. Eurich DT, McAlister FA, Blackburn DF, et al. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ 2007; 335: 497. Go to original source... Go to PubMed...
    28. Scirica BM, Bhatt DL, Braunwald E, et al.; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369: 1317-1326. Go to original source... Go to PubMed...
    29. White WB, Cannon CP, Heller SR, et al.; EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013; 369: 1327-1335. Go to original source... Go to PubMed...
    30. Green JB, Bethel MA, Armstrong PW, et al.; TECOS Study Group. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2015; 373: 232-242. Go to original source... Go to PubMed...
    31. Pfeffer MA, Claggett B, Diaz R, et al.; ELIXA Investigators. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med 2015; 373: 2247-2257. Go to original source... Go to PubMed...
    32. Marso SP, Daniels GH, Brown-Frandsen K, et al.; for the LEADER Steering Committee on behalf of the LEADER Trial Investigators. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2016; DOI:10.1056/NEJMoa1603827. Go to original source... Go to PubMed...
    33. Zinman B, Wanner C, Lachin JM, et al.; EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015; 373: 2117-2128. Go to original source... Go to PubMed...
    34. Fitchett D, Zinman B, Wanner C, et al.; EMPA-REG OUTCOME(R) trial investigators. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME(R) trial. Eur Heart J 2016; Jan 26. pii: ehv728. Go to original source... Go to PubMed...
    35. Rajasekeran H, Lytvyn Y, Cherney DZ. Sodium-glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis. Kidney Int 2016; 89: 524-526. Go to original source... Go to PubMed...
    36. DeFronzo RA. The EMPA-REG study: What has it told us? A diabetologist's perspective. J Diabetes Complications 2016; 30: 1-2. Go to original source... Go to PubMed...
    37. McMurray J. EMPA-REG - the "diuretic hypothesis". J Diabetes Complications 2016; 30: 3-4. Go to original source... Go to PubMed...
    38. http://www.diab.cz/dokumenty/doporuceni_DM_2015-2.pdf.
    39. Authors/Task Force Members; Document Reviewers. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016; doi:10.1002/ejhf.592. Go to original source... Go to PubMed...

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.